The unexpected observation of potent anti-tumor activity mediated by H11-HLE, which is devoid of Fc-effector functions, prompted us to interrogate whether Fc effector functions are required for anti-tumor activity observed for ipilimumab, the only clinically approved anti-human CTLA-4 antibody. This evidence concerns the gene CTLA4 and neoplasm.